Back

Long-term outcomes in newly diagnosed pulmonary arterial hypertension (PAH) patients receiving initial triple oral combination therapy: Insights from the randomised controlled TRITON study

29 August 2020 (08:30 - 08:42)
Organised by:
Congress Presentation Part of: Deep Dive into Pulmonary Arterial Hypertension and Myocardial Disease Pulmonary Hypertension ESC Premium Access ESC Congress 2020

About the speaker

Photo
Professor Nazzareno Galie

Alma Mater Studiorum, University of Bologna, Bologna (Italy)

2 More presentations in this session

Presentation thumbnail
Atrial strain in cardiacATTR amyloidosis from pathophysiology to prognosis: is it time to rethink our approach to disease?
Doctor F. Bandera (Milan, IT)
Abstract Slides Video
Presentation thumbnail
High prevalence of familial and genetic disease in children with cardiomyopathies: Baseline paediatric data from the ESC EORP Cardiomyopathy and Myocarditis Registry
Associate Professor J. Kaski (London, GB)
Abstract Slides Video

Access the full session

Session thumbnail
Deep Dive into Pulmonary Arterial Hypertension and Myocardial Disease

The Event

Event poster

ESC Congress 2020

29 August 2020 08:30 CET
You may be interested in
thumbnail
Congress Presentation
Impact of triple vasodilator therapy on prognosis stratification of pulmonary arterial hypertension associated with congenital heart disease
thumbnail
Congress Presentation
Comparison of triple oral and triple parenteral combination therapy in pulmonary arterial hypertension
thumbnail
Congress Presentation
Evaluating the safety and long-term efficacy of triple vasodilator therapy for pulmonary arterial hypertension associated with congenital heart disease

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources